Serious adverse events · Patients with quiescent ulcerative colitis
Oral 5‐aminosalicylic acid showed no clear difference in serious adverse events compared with comparator 5‐aminosalicylic acid formulation (low certainty).
1 finding from 1 review
Quality of life Drug resistance/microbial sensitivity Serious adverse events Lung function Hospitalisations Adverse events/side effects Number of participants colonised with P aeruginosa · patients with chronic obstructive pulmonary disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Quality of life Drug resistance/microbial sensitivity Serious adverse events Lung function Hospitalisations Adverse events/side effects Number of participants colonised with P aeruginosa · patients with chronic obstructive pulmonary disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events · people with chronic gout
Allopurinol showed no clear difference in serious adverse events compared with placebo (moderate certainty).
1 finding from 1 review
Serious adverse events · adult parapneumonic effusions and empyema
Fibrinolytics showed no clear difference in serious adverse events compared with placebo (low certainty).
1 finding from 1 review
Serious adverse events · people with active UC
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events · Patients with quiescent ulcerative colitis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events · Patients with quiescent ulcerative colitis
Oral 5‐aminosalicylic acid showed no clear difference in serious adverse events compared with placebo (low certainty).
1 finding from 1 review
Serious adverse events · Patients with presumed drug‐sensitive TB
It is very uncertain whether fluoroquinolone plus standard regimen changes serious adverse events compared with standard regimen alone (very low certainty).
1 finding from 1 review
Serious adverse events · Patients with presumed drug‐sensitive TB
Fluoroquinolone substitution for isoniazid in a standard six month… showed no clear difference in serious adverse events compared with standard regimen (low certainty).
1 finding from 1 review
Serious adverse events · Patients with presumed drug‐sensitive TB
It is very uncertain whether fluoroquinolone substitution for ethambutol in a standard six month… changes serious adverse events compared with standard regimen (very low certainty).
1 finding from 1 review
Serious adverse events · adults aged 18 years and above with diagnosis of non‐cystic fibrosis bronchiectasis
1 finding from 1 review
Serious adverse eventsr
CoronaVac – Sinovac showed no clear difference in serious adverse eventsr compared with placebo (low certainty).
1 finding from 1 review
Serious adverse eventsi
WIBP‐CorV – Sinopharm‐Wuhan showed no clear difference in serious adverse eventsi compared with placebo (low certainty).
1 finding from 1 review
Serious adverse eventsk
BBIBP‐CorV – Sinopharm‐Beijing showed no clear difference in serious adverse eventsk compared with placebo (low certainty).
1 finding from 1 review
Serious adverse events · Patients with quiescent ulcerative colitis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events ‐ not reported · patients with Shigella dysentery
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All serious adverse events · adults with acute spontaneous intracerebral haemorrhage
Summary of findings table ‐ Antifibrinolytic drug(s) showed no clear difference in all serious adverse events compared with placebo/open control (high certainty).
1 finding from 1 review
Serious adverse events clinical criteria · patients with Shigella dysentery
It is very uncertain whether fluoroquinolones changes serious adverse events clinical criteria compared with beta‐lactams (very low certainty).
1 finding from 1 review
Incidence of serious adverse events · adults with alopecia areata
1 finding from 1 review